Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role ...
Oct 29, 2024The emergence of incretin-based therapies, specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs) andglucose-dependentinsulinotropicpolypeptide (GIP), as a new class of obesity medications, is dramatically changing obesity care. Use of these medications, known categorically as anti-obesity medications, as part of comprehensive obesity management is associated with significantly ...
source: https://www.jandonline.org